- Wellcome has reported that its new antiHIV nucleoside analog reverse transcriptase inhibitor, 1592, has a potent and selective action against clinical isolates of HIV. In addition, says the company, the compound is not cross-resistant to zidovudine-resistant virus and in vitro development of resistance to the drug is very slow.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze